Savoy Biotech

Savoy Biotech is a clinical-stage biotechnology company focused on developing nasal-based therapeutics and prophylactics for respiratory viral infections. The company's lead product candidate, Savoy-1, is a proprietary nasal spray designed to neutralize viruses like SARS-CoV-2 at the point of entry in the nasal cavity. By creating a biochemical barrier, the treatment aims to reduce viral load, prevent infection, and limit the transmission of respiratory pathogens. Savoy Biotech's technology is intended to complement existing vaccine strategies by providing an immediate, localized defense mechanism. The company has progressed its lead candidate into Phase 2 clinical testing to evaluate its efficacy in real-world settings.